Post-operative Nausea and Vomiting (PONV) Market (Treatment: Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacologic Treatment, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast,

Post-operative Nausea and Vomiting (PONV) Market (Treatment: Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacologic Treatment, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Post-operative Nausea and Vomiting (PONV) Market – Scope of Report

TMR’s report on the global post-operative nausea and vomiting (PONV) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global post-operative nausea and vomiting (PONV) market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global post-operative nausea and vomiting (PONV) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the post-operative nausea and vomiting (PONV) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global post-operative nausea and vomiting (PONV) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global post-operative nausea and vomiting (PONV) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global post-operative nausea and vomiting (PONV) market.

The report delves into the competitive landscape of the global post-operative nausea and vomiting (PONV) market. Key players operating in the global post-operative nausea and vomiting (PONV) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global post-operative nausea and vomiting (PONV) market profiled in this report.

Key Questions Answered in Global post-operative nausea and vomiting (PONV) Market Report
  • What is the sales/revenue generated by post-operative nausea and vomiting (PONV) across all regions during the forecast period?
  • What are the opportunities in the global post-operative nausea and vomiting (PONV) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Post-operative Nausea and Vomiting (PONV) Market – Research Objectives and Research Approach

The comprehensive report on the global post-operative nausea and vomiting (PONV) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global post-operative nausea and vomiting (PONV) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global post-operative nausea and vomiting (PONV) market.


1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market
4. Market Overview
4.1. Market Segmentation
  4.1.1. Segment Definition
  4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
4.4. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, 2022-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2023–2031
  6.3.1. Serotonin Antagonists
  6.3.2. Steroids
  6.3.3. Dopamine Antagonists
  6.3.4. NK-1 Receptor Antagonists
  6.3.5. Non-pharmacologic Treatment
  6.3.6. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
  7.3.1. Hospital Pharmacies
  7.3.2. Online Pharmacies
  7.3.3. Retail Pharmacies & Drug Stores
7.4. Market Attractiveness, by Distribution Channel
8. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2023–2031
  8.2.1. North America
  8.2.2. Europe
  8.2.3. Asia Pacific
  8.2.4. Latin America
  8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
9.1. Introduction
  9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2023–2031
  9.2.1. Serotonin Antagonists
  9.2.2. Steroids
  9.2.3. Dopamine Antagonists
  9.2.4. NK-1 Receptor Antagonists
  9.2.5. Non-pharmacologic Treatment
  9.2.6. Others
9.3. Market Value Forecast, by Distribution Channel, 2023–2031
  9.3.1. Hospital Pharmacies
  9.3.2. Online Pharmacies
  9.3.3. Retail Pharmacies & Drug Stores
9.4. Market Value Forecast, by Country, 2023–2031
  9.4.1. U.S.
  9.4.2. Canada
9.5. Market Attractiveness Analysis
  9.5.1. By Treatment Type
  9.5.2. By Distribution Channel
  9.5.3. By Country
10. Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Introduction
  10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2023–2031
  10.2.1. Serotonin Antagonists
  10.2.2. Steroids
  10.2.3. Dopamine Antagonists
  10.2.4. NK-1 Receptor Antagonists
  10.2.5. Non-pharmacologic Treatment
  10.2.6. Others
10.3. Market Value Forecast, by Distribution Channel, 2023–2031
  10.3.1. Hospital Pharmacies
  10.3.2. Online Pharmacies
  10.3.3. Retail Pharmacies & Drug Stores
10.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  10.4.1. Germany
  10.4.2. U.K.
  10.4.3. France
  10.4.4. Italy
  10.4.5. Spain
  10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
  10.5.1. By Treatment Type
  10.5.2. By Distribution Channel
  10.5.3. By Country/Sub-region
11. Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Introduction
  11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2023–2031
  11.2.1. Serotonin Antagonists
  11.2.2. Steroids
  11.2.3. Dopamine Antagonists
  11.2.4. NK-1 Receptor Antagonists
  11.2.5. Non-pharmacologic Treatment
  11.2.6. Others
11.3. Market Value Forecast, by Distribution Channel, 2023–2031
  11.3.1. Hospital Pharmacies
  11.3.2. Online Pharmacies
  11.3.3. Retail Pharmacies & Drug Stores
11.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  11.4.1. China
  11.4.2. Japan
  11.4.3. India
  11.4.4. Australia & New Zealand
  11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
  11.5.1. By Treatment Type
  11.5.2. By Distribution Channel
  11.5.3. By Country/Sub-region
12. Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Introduction
  12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2023–2031
  12.2.1. Serotonin Antagonists
  12.2.2. Steroids
  12.2.3. Dopamine Antagonists
  12.2.4. NK-1 Receptor Antagonists
  12.2.5. Non-pharmacologic Treatment
  12.2.6. Others
12.3. Market Value Forecast, by Distribution Channel, 2023–2031
  12.3.1. Hospital Pharmacies
  12.3.2. Online Pharmacies
  12.3.3. Retail Pharmacies & Drug Stores
12.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
  12.5.1. By Treatment Type
  12.5.2. By Distribution Channel
  12.5.3. By Country/Sub-region
13. Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Introduction
  13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2023–2031
  13.2.1. Serotonin Antagonists
  13.2.2. Steroids
  13.2.3. Dopamine Antagonists
  13.2.4. NK-1 Receptor Antagonists
  13.2.5. Non-pharmacologic Treatment
  13.2.6. Others
13.3. Market Value Forecast, by Distribution Channel, 2023–2031
  13.3.1. Hospital Pharmacies
  13.3.2. Online Pharmacies
  13.3.3. Retail Pharmacies & Drug Stores
13.4. Market Value Forecast, by Country/Sub-region, 2023–2031
  13.4.1. GCC Countries
  13.4.2. South Africa
  13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
  13.5.1. By Treatment Type
  13.5.2. By Distribution Channel
  13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
  14.3.1. Acacia Pharma
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
  14.3.2. F. Hoffmann-La Roche AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
  14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
  14.3.4. Ani Pharmaceuticals, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
  14.3.5. Camurus AB
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
  14.3.6. Sanofi S.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
  14.3.7. Helsinn Holding S.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
  14.3.8. Eisai Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
  14.3.9. GlaxoSmithKline Corporation
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
  14.3.10. Merck and Co.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings